Total Payments
$1,301
2022 Payments
$37.99
Companies
15
Transactions
71
Medicare Patients
2,137
Medicare Billing
$455,219
Payment Breakdown by Category
Food & Beverage$1,269 (97.5%)
Education$32.12 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,269 | 69 | 97.5% |
| Education | $32.12 | 2 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan Inc. | $352.69 | 19 | $0 (2019) |
| Merck Sharp & Dohme LLC | $228.61 | 14 | $0 (2022) |
| Theravance Biopharma, Inc. | $166.26 | 11 | $0 (2018) |
| Organogenesis Inc. | $146.34 | 4 | $0 (2018) |
| Melinta Therapeutics, Inc. | $69.47 | 5 | $0 (2019) |
| ABBVIE INC. | $69.34 | 4 | $0 (2022) |
| Paratek Pharmaceuticals, Inc. | $59.78 | 3 | $0 (2021) |
| Gilead Sciences, Inc. | $50.54 | 2 | $0 (2020) |
| The Medicines Company | $43.87 | 3 | $0 (2017) |
| ViiV Healthcare Company | $32.71 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $37.99 | 2 | Merck Sharp & Dohme LLC ($21.11) |
| 2021 | $48.55 | 3 | Paratek Pharmaceuticals, Inc. ($16.96) |
| 2020 | $56.31 | 2 | Gilead Sciences, Inc. ($32.26) |
| 2019 | $219.10 | 12 | Allergan Inc. ($91.18) |
| 2018 | $300.15 | 17 | Allergan Inc. ($116.72) |
| 2017 | $638.99 | 35 | Allergan Inc. ($144.79) |
All Payment Transactions
71 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/06/2022 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/03/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/23/2021 | Merck Sharp & Dohme Corporation | DIFICID (Drug), RECARBRIO, ZINPLAVA | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/16/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: VIROLOGY | ||||||
| 02/16/2021 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: ANTIBIOTIC | ||||||
| 10/21/2020 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: ANTIBIOTIC | ||||||
| 10/07/2020 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.26 | General |
| 11/19/2019 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/05/2019 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: ANTIBIOTIC | ||||||
| 10/30/2019 | Melinta Therapeutics, Inc. | Orbactiv (Drug), Baxdela | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: ANTIBIOTICS | ||||||
| 07/23/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/10/2019 | Melinta Therapeutics, Inc. | Baxdela (Drug), Orbactiv | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: ANTIBIOTICS | ||||||
| 04/17/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 03/12/2019 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/22/2019 | Melinta Therapeutics, Inc. | Orbactiv (Drug) | Food and Beverage | In-kind items and services | $12.36 | General |
| Category: ANTIBIOTICS | ||||||
| 02/13/2019 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/22/2019 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/16/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: Virology | ||||||
| 01/10/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $28.99 | General |
| 11/14/2018 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/31/2018 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/18/2018 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $16.79 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/12/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 08/29/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/07/2018 | Organogenesis Inc. | Apligraf (Medical Supply) | Food and Beverage | Cash or cash equivalent | $16.20 | General |
| Category: Wound Care | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 378 | 847 | $135,040 | $69,009 |
| 2022 | 4 | 466 | 1,264 | $192,400 | $98,194 |
| 2021 | 5 | 648 | 1,798 | $273,270 | $142,334 |
| 2020 | 4 | 645 | 1,741 | $276,440 | $145,682 |
Total Patients
2,137
Total Services
5,650
Medicare Billing
$455,219
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 140 | 536 | $58,960 | $32,571 | 55.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 164 | 182 | $54,600 | $23,624 | 43.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 63 | $10,080 | $6,202 | 61.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 51 | $7,650 | $4,687 | 61.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $3,750 | $1,924 | 51.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 173 | 811 | $89,210 | $44,664 | 50.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 204 | 230 | $69,000 | $34,353 | 49.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 50 | 149 | $22,350 | $11,792 | 52.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 74 | $11,840 | $7,385 | 62.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 224 | 1,079 | $118,690 | $60,136 | 50.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 250 | 292 | $87,600 | $44,685 | 51.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 99 | 305 | $45,750 | $24,508 | 53.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 56 | 103 | $16,480 | $10,493 | 63.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 19 | 19 | $4,750 | $2,512 | 52.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 158 | 594 | $89,100 | $47,502 | 53.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 259 | 298 | $89,400 | $46,854 | 52.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 176 | 758 | $83,380 | $43,724 | 52.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 52 | 91 | $14,560 | $7,602 | 52.2% |
About Dr. Jakaulla Khan, MD
Dr. Jakaulla Khan, MD is a Infectious Disease healthcare provider based in Clifton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306936349.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jakaulla Khan, MD has received a total of $1,301 in payments from pharmaceutical and medical device companies, with $37.99 received in 2022. These payments were reported across 71 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($1,269).
As a Medicare-enrolled provider, Khan has provided services to 2,137 Medicare beneficiaries, totaling 5,650 services with total Medicare billing of $455,219. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Clifton, NJ
- Active Since 10/13/2006
- Last Updated 10/19/2016
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1306936349
Products in Payments
- TEFLARO (Drug) $187.35
- ZERBAXA (Drug) $180.94
- VIBATIV (Drug) $166.26
- DALVANCE (Drug) $144.42
- Apligraf (Biological) $130.14
- NUZYRA (Drug) $59.78
- DIFICID (Drug) $47.67
- Baxdela (Drug) $44.52
- AVYCAZ (Drug) $37.80
- Mavyret (Drug) $37.23
- TIVICAY (Drug) $32.71
- MINOCIN IV (Drug) $29.86
- Orbactiv (Drug) $24.95
- Xerava (Drug) $16.77
- Apligraf (Medical Supply) $16.20
- MAVYRET (Drug) $15.23
- ORBACTIV (Drug) $14.01
- Santyl (Drug) $12.88
- SNAP (Device) $11.64
- PluroGel Burn & Wound Dressings (Device) $11.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Clifton
Dr. Sessine Najjar, M.d, M.D
Infectious Disease — Payments: $15,083
Infectious Disease $15,083
Dr. Rodolfo Munera, Md, MD
Infectious Disease — Payments: $5,310
Infectious Disease $5,310
Dr. Frederick Okoye, Md, MD
Infectious Disease — Payments: $2,346
Infectious Disease $2,346
Gabriel Karkenny
Infectious Disease — Payments: $694.81
Infectious Disease $694.81
Sabah Varoqua, M.d, M.D
Infectious Disease — Payments: $237.16
Infectious Disease $237.16
Dr. Yasmeen Sultana, Md, MD
Infectious Disease — Payments: $17.91
Infectious Disease $17.91